Ibrutinib is an oral, first-line, targeted therapy for chronic lymphocytic leukemia (CLL). Commonly reported adverse events are diarrhea, fatigue, and musculoskeletal pain, but rarely it has been associated with visual disturbances. Here, we present a rare case of spontaneous hyphema in a 60-year-old patient with a known diagnosis of CLL on ibrutinib treatment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10735723 | PMC |
http://dx.doi.org/10.1155/2023/1691996 | DOI Listing |
Retin Cases Brief Rep
December 2024
Liverpool Ocular Oncology Research Centre, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Purpose: The Foldable Capsular Vitreous Bag (FCVB) implant is useful in maintaining ocular structure in cases of chronic hypotony secondary to trauma or repeated surgery. There are few published reports of long-term outcomes and no indication of the chronic cellular changes of the adjacent tissues associated with FCVB implantation. We describe one of few FCVB cases in the UK and present histological findings associated with it following secondary enucleation.
View Article and Find Full Text PDFJ Glaucoma
October 2024
Department of Ophthalmology, Mayo Clinic 200 First St SW, Rochester, MN, 55905.
Minimally invasive glaucoma surgery (MIGS) offers options for glaucoma treatment that have generally improved safety profiles compared with filtering surgery. MIGS vary in design and procedure, but all angle-based MIGS function by bypassing or removing aqueous humor outflow resistance at the level of the trabecular meshwork. This can lower intraocular pressure but also remove the blood-aqueous barrier.
View Article and Find Full Text PDFPrcis: Gonioscopy-assisted transluminal trabeculotomy yielded a 45% reduction in intraocular pressure in primary congenital glaucoma, with a success rate of 86.6%. Hyphema was the most common complication.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!